SCHEMBL20769878

SCHEMBL20769878

Clc1cc(Cl)nc(OCCc2ccccn2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.47
TYK2 P29597 1/20 0.47
BRSK1 Q8TDC3 1/20 0.47
IRAK4 Q9NWZ3 1/20 0.47
PDE10A Q9Y233 3/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
MKNK1 Q9BUB5 1/20 0.45
MKNK2 Q9HBH9 1/20 0.45
HRH1 P35367 2/20 0.44
HRH3 Q9Y5N1 1/20 0.41
HPGD P15428 2/20 0.40
LMNA P02545 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
ALDH1A1 P00352 1/20 0.40
ALOX15 P16050 1/20 0.40
CYP1A2 P05177 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11929832 0.90 PDE10A (0.50) SYKTYK2BRSK1IRAK4PDE10A
SCHEMBL3555625 0.83 SYK (0.51) SYKLMNAALDH1A1
SCHEMBL11926405 0.82 PDE10A (0.42) SYKTYK2BRSK1IRAK4PDE10A
SCHEMBL1617807 0.81 TYK2 (0.72) SYKTYK2BRSK1IRAK4LMNA
SCHEMBL30273129 0.81 TYK2 (0.72) SYKTYK2BRSK1IRAK4LMNA
SCHEMBL30087302 0.78 TYK2 (0.42) SYKTYK2BRSK1IRAK4PDE10A
SCHEMBL20769922 0.78 TYK2 (0.42) SYKTYK2BRSK1IRAK4PDE10A
SCHEMBL21554435 0.75 MKNK1 (0.51) SYKTYK2BRSK1IRAK4PDE10A
SCHEMBL13406340 0.73 CYP1A2 (0.57) HRH3LMNATAAR1ALDH1A1ALOX15
SCHEMBL8569746 0.73 ALDH1A1 (0.48) HRH1HRH3LMNATAAR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260130921-A1 TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS AcuraStem Incorporated (US) 2026-05-14 US disclosed
US-20240352026-A1 PIKFYVE KINASE INHIBITORS AcuraStem Incorporated 2024-10-24 US disclosed
US-20240197747-A1 TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS AcuraStem, Inc. (US) 2024-06-20 US disclosed
US-20230135152-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
US-20230135152-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
US-20230135152-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
EP-4103281-A1 PIKFYVE KINASE INHIBITORS Acurastem Inc. (US) 2022-12-21 EP disclosed
US-20210338683-A1 TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-11-04 US disclosed
US-20210338683-A1 TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-11-04 US disclosed
WO-2021163727-A1 PIKFYVE KINASE INHIBITORS AcuraStem Incorporated (US) 2021-08-19 WO disclosed
WO-2021163727-A1 PIKFYVE KINASE INHIBITORS AcuraStem Incorporated (US) 2021-08-19 WO disclosed
EP-3676264-A1 PIKFYVE KINASE INHIBITORS Acurastem Inc. (US) 2020-07-08 EP disclosed
US-20200199136-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-06-25 US disclosed
US-20200199136-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-06-25 US disclosed
WO-2019046316-A1 PIKFYVE KINASE INHIBITORS ACURASTEM INC. (US) 2019-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135152-A1 PIKFYVE KINASE INHIBITORS PIKFYVE, PIP5K1B, PIP5K1C SYK 375/4885TYK2 513/4885BRSK1 470/4885
US-20200199136-A1 PIKFYVE KINASE INHIBITORS PIKFYVE, PIP5K1B, PIK3CA SYK 397/4885TYK2 395/4885BRSK1 458/4885
US-20240352026-A1 PIKFYVE KINASE INHIBITORS PIKFYVE, PIP5K1B, PIK3CA SYK 397/4885TYK2 395/4885BRSK1 458/4885
US-20240197747-A1 TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS PIKFYVE, TMPRSS2, TMPRSS4 SYK 166/4885TYK2 416/4885BRSK1 382/4885
US-20260130921-A1 TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS TMPRSS2, TMPRSS11D, TMPRSS6 SYK 230/4885TYK2 542/4885BRSK1 618/4885
US-20210338683-A1 TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS PIKFYVE, TMPRSS2, TMPRSS4 SYK 166/4885TYK2 416/4885BRSK1 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.